USPTO serial 97815175
V
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 7, 2025
- Examiner
- LEVINE, HOWARD B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with V?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA
South San Francisco, CA
South San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rosaleen H. Chou
Rosaleen H. Chou Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorKnobbe, Martens, Olson & Bear, LLPIrvine, CA 92614Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for scientific or research use; Diagnostic kits and test kits primarily composed of reagents for determination of genomic and transcriptomic information for scientific or research purposes; Testing kits comprised primarily of preparations, reagents, test strips, collection tubes, buffers, tube holders, transport bags and assays for scientific or research use in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Biological agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for scientific and research use; Diagnostic reagents and preparations, other than for medical and veterinary use; Kits comprised primarily of biological reagents and comprised secondarily of a protocol in the form of printed instructions for use thereof for scientific and research purposes; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for scientific or research purposes; Reagents and molecule or cell markers for scientific or research purposes | ACTIVE | — |
| 005 | Kits for in vitro diagnostic testing for cancers and other diseases; Reagents for medical use; Molecular diagnostic assays for testing of bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Diagnostic medical preparations for use in the field of bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Diagnostic agents, preparations and substances for medical purposes; Diagnostic test kits consisting primarily of reagents for use in testing bodily fluids, tissue, cells, blood, disease, cancer, genetics, and pathogens; Medical diagnostic test kits consisting primarily of reagents for detecting pathogens; Clinical medical diagnostic reagents, medical diagnostic assays for medical and diagnostic purposes for testing genetic material; Chemicals, assays, reagents and kits consisting primarily of chemicals, assays, and reagents for medical testing and diagnostic purposes in the fields of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic reagents, and kits comprised of medical diagnostic reagents, collection tubes, buffers, tube holders, transport bags, and instruction sheets, for diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Medical diagnostic testing kits comprised primarily of reagents and assays for use in diagnostics and diagnostic testing in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use | ACTIVE | — |
| 042 | Clinical medical research; clinical research in the field of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research trials and studies, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Scientific laboratory research; Scientific laboratory services; Scientific laboratory testing services for disease, cancer, genetics, and pathogens; Scientific laboratory testing and testing, analysis, monitoring, and results reporting services for use in research and development for oncology, cancers, and diseases; Scientific and medical research and development services; Research and development services for others in the field of diagnostic tests, chemicals, compounds and devices; Research and development of new diagnostic tests, clinical products, diagnostic agents and assays; Nucleic acid sequencing, screening, and analysis services for medical research purposes; Genomic and transcriptomic sequencing, screening, and analysis services for medical research purposes; Genetic analysis and reporting services for medical research purposes; Providing medical research services for others featuring research in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Chemical screening analysis and diagnostic services for others for scientific research purposes; Scientific and technological research in the field of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases and diagnostic services for scientific research purposes; Advisory, consultative and telephone help desk services relating to the use of assays and reagents for use in biochemical analysis and diagnostic services; Information and advisory services in the fields of medical research, clinical research, medical laboratory research, and scientific research in the fields of laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Providing online non-downloadable computer software for medical diagnostics and research in the field of genomics, diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Providing online non-downloadable software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; Providing online non-downloadable software for use in data analysis in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases | ACTIVE | — |
| 044 | Medical services; Medical diagnostic testing services; Medical testing for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes; Medical diagnostic testing services in the fields of oncology, cancer, and diseases; Genetic analysis and reporting services for medical diagnostic purposes; Medical diagnostic testing, monitoring and reporting services in the fields of diagnostics, medical diagnostics, clinical diagnostics, companion diagnostics, medical treatment, medical research, clinical research, medical laboratory research, laboratory medicine, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, biology, oncology, cancers, thyroid cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, kidney cancer, colon cancer, interstitial lung diseases, lymphoma, diseases, infectious diseases, and related diseases; Nucleic acid sequencing and analysis services for medical diagnostic and treatment purposes; Genomic and transcriptomic sequencing and analysis services for medical diagnostic and treatment purposes; Genetic analysis and reporting services for medical diagnostic and treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Veracyte, Inc.
- Other trademarks owned by Veracyte, Inc.
- Other trademarks owned by Veracyte, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named V
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 30, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 30, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 30, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 30, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 7, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 7, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 19, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 19, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 13, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 2, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 2, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 3, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 3, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 3, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 22, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Feb 22, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Nov 30, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 30, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 30, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 29, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 19, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2023 | NWAP | NEW APPLICATION ENTERED | — |